Skip navigation

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

Results 1 - 6 of 6 for LISOCABTAGENE MARALEUCEL
  1. Lisocabtagene maraleucel is used to treat certain types of large B-cell lymphoma (a type of cancer that ... has returned or is unresponsive to other treatments. Lisocabtagene maraleucel is also used to treat chronic lymphocytic leukemia ( ...
  2. Lymphoma Research Foundation (Lymphoma Research Foundation)  
    ... News The U.S. Food and Drug Administration Approves Lisocabtagene Maraleucel (Breyanzi) for Mantle Cell Lymphoma 05/31/2024 ... News The U.S. Food and Drug Administration Approves Lisocabtagene Maraleucel (Breyanzi) for Follicular Lymphoma Subscribe to Our Emails. ...
  3. Drugs Approved for Leukemia From the National Institutes of Health (National Cancer Institute)  
    Leukemia/Treatments and Therapies ... Leukemia ... National Cancer Institute ... From the National Institutes of Health ... This page lists cancer drugs approved by the FDA ...
  4. Drugs Approved for Non-Hodgkin Lymphoma From the National Institutes of Health (National Cancer Institute)  
    A list of cancer drugs approved by the Food and Drug Administration (FDA) for non-Hodgkin lymphoma. The list includes generic names, brand names, and common ...
  5. A to Z List of Cancer Drugs From the National Institutes of Health (National Cancer Institute)  
    Cancer/Treatments and Therapies ... Cancer ... Cancer Chemotherapy/Start Here ... Cancer Chemotherapy ... National Cancer Institute ... From the National Institutes of Health ... List ...
  6. Advances in Lymphoma Research From the National Institutes of Health (National Cancer Institute)  
    Lymphoma/Statistics and Research ... Lymphoma ... Hodgkin Lymphoma/Statistics and Research ... Hodgkin Lymphoma ... National Cancer Institute ... From the National Institutes ...